Your browser doesn't support javascript.
loading
Hyperuricemia and dementia - a case-control study.
Engel, Bettina; Gomm, Willy; Broich, Karl; Maier, Wolfgang; Weckbecker, Klaus; Haenisch, Britta.
Afiliação
  • Engel B; Institute of General Practice and Family Medicine, University of Bonn, Bonn, Germany.
  • Gomm W; Department of Health Services Research, Division of General Medicine, University of Oldenburg, Oldenburg, Germany.
  • Broich K; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Maier W; Federal Institute for Drugs and Medical Devices (BfArM), Kurt-Georg-Kiesinger-Allee 3, D-53175, Bonn, Germany.
  • Weckbecker K; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Haenisch B; Department of Psychiatry, University of Bonn, Bonn, Germany.
BMC Neurol ; 18(1): 131, 2018 Aug 31.
Article em En | MEDLINE | ID: mdl-30170563
BACKGROUND: There is evidence that uric acid may have antioxidant and neuroprotective effects and might therefore alter the risk for neurodegenerative diseases such as dementia. So far, the relation between serum uric acid (SUA) levels or hyperuricemia and dementia remains elusive. Most studies focused on the disease or SUA levels. Effects of anti-hyperuricemic treatment have not been considered yet. This study investigated the association between hyperuricemia and dementia taking into account anti-hyperuricemic treatment. METHODS: We used longitudinal German public health insurance data and analyzed the association between hyperuricemia with and without different treatment options and dementia in a case-control design. Applying logistic regression the analysis was adjusted for several potential confounders including various comorbidities and polypharmacy. RESULTS: We identified 27,528 cases and 110,112 matched controls of which 22% had a diagnosis of hyperuricemia or gout and 17% received anti-hyperuricemic drugs. For patients with a diagnosis of hyperuricemia we found a slightly reduced risk for dementia (adjusted odds ratio [OR] 0.94, 95% confidence interval [CI] 0.89 to 0.98). The risk reduction was more pronounced for patients treated with anti-hyperuricemic drugs (adjusted OR 0.89, 95% CI 0.85 to 0.94, for regular treatment). CONCLUSIONS: Our results showed a slight reduction for dementia risk in patients with hyperuricemia, both with and without anti-hyperuricemic treatment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Demência / Hiperuricemia Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Demência / Hiperuricemia Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article